Trial Profile
A randomized phase III trial of gemcitabine and docetaxel versus gemcitabine and paclitaxel in patients with metastatic breast cancer: a comparison of different schedules.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2013
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Jun 2012 Status changed from completed to discontinued.
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 03 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.